Cargando…
Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis
Multiple sclerosis (MS) is a life-long, potentially debilitating disease of the central nervous system (CNS). MS is considered to be an immune-mediated disease, and the presence of autoreactive peripheral lymphocytes in CNS compartments is believed to be critical in the process of demyelination and...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057629/ https://www.ncbi.nlm.nih.gov/pubmed/24723124 http://dx.doi.org/10.1007/s40263-014-0160-8 |
_version_ | 1782320999387103232 |
---|---|
author | Du Pasquier, Renaud A. Pinschewer, Daniel D. Merkler, Doron |
author_facet | Du Pasquier, Renaud A. Pinschewer, Daniel D. Merkler, Doron |
author_sort | Du Pasquier, Renaud A. |
collection | PubMed |
description | Multiple sclerosis (MS) is a life-long, potentially debilitating disease of the central nervous system (CNS). MS is considered to be an immune-mediated disease, and the presence of autoreactive peripheral lymphocytes in CNS compartments is believed to be critical in the process of demyelination and tissue damage in MS. Although MS is not currently a curable disease, several disease-modifying therapies (DMTs) are now available, or are in development. These DMTs are all thought to primarily suppress autoimmune activity within the CNS. Each therapy has its own mechanism of action (MoA) and, as a consequence, each has a different efficacy and safety profile. Neurologists can now select therapies on a more individual, patient-tailored basis, with the aim of maximizing potential for long-term efficacy without interruptions in treatment. The MoA and clinical profile of MS therapies are important considerations when making that choice or when switching therapies due to suboptimal disease response. This article therefore reviews the known and putative immunological MoAs alongside a summary of the clinical profile of therapies approved for relapsing forms of MS, and those in late-stage development, based on published data from pivotal randomized, controlled trials. |
format | Online Article Text |
id | pubmed-4057629 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-40576292014-06-18 Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis Du Pasquier, Renaud A. Pinschewer, Daniel D. Merkler, Doron CNS Drugs Review Article Multiple sclerosis (MS) is a life-long, potentially debilitating disease of the central nervous system (CNS). MS is considered to be an immune-mediated disease, and the presence of autoreactive peripheral lymphocytes in CNS compartments is believed to be critical in the process of demyelination and tissue damage in MS. Although MS is not currently a curable disease, several disease-modifying therapies (DMTs) are now available, or are in development. These DMTs are all thought to primarily suppress autoimmune activity within the CNS. Each therapy has its own mechanism of action (MoA) and, as a consequence, each has a different efficacy and safety profile. Neurologists can now select therapies on a more individual, patient-tailored basis, with the aim of maximizing potential for long-term efficacy without interruptions in treatment. The MoA and clinical profile of MS therapies are important considerations when making that choice or when switching therapies due to suboptimal disease response. This article therefore reviews the known and putative immunological MoAs alongside a summary of the clinical profile of therapies approved for relapsing forms of MS, and those in late-stage development, based on published data from pivotal randomized, controlled trials. Springer International Publishing 2014-04-11 2014 /pmc/articles/PMC4057629/ /pubmed/24723124 http://dx.doi.org/10.1007/s40263-014-0160-8 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Review Article Du Pasquier, Renaud A. Pinschewer, Daniel D. Merkler, Doron Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis |
title | Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis |
title_full | Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis |
title_fullStr | Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis |
title_full_unstemmed | Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis |
title_short | Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis |
title_sort | immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057629/ https://www.ncbi.nlm.nih.gov/pubmed/24723124 http://dx.doi.org/10.1007/s40263-014-0160-8 |
work_keys_str_mv | AT dupasquierrenauda immunologicalmechanismofactionandclinicalprofileofdiseasemodifyingtreatmentsinmultiplesclerosis AT pinschewerdanield immunologicalmechanismofactionandclinicalprofileofdiseasemodifyingtreatmentsinmultiplesclerosis AT merklerdoron immunologicalmechanismofactionandclinicalprofileofdiseasemodifyingtreatmentsinmultiplesclerosis |